

Special Issue

Advanced Diagnostic and Treatment Methods in Alzheimer's Disease

Message from the Guest Editor

Alzheimer's disease (AD) is a form of dementia and the most common progressive neurodegenerative disease. Alzheimer's disease affects approximately 50 million individuals worldwide, according to estimates. It is predicted that this number will rise to 150 million by 2050 unless new preventative medicines are developed or even very effective diagnostic tools. To provide a dynamic insight into the AD Challenge, this Special Issue aims to reveal anti-AD treatments and additional computational tools for early diagnosis and prediction of the disease and other comorbidities. We invite authors to submit original research and review articles that focus on the following potential topics include, but are not limited to:

- Alzheimer's disease
- Amyloid-beta
- Antidiabetic drugs in Neurodegeneration
- Cancer and Alzheimer's Disease
- Computational Biomedicine
- Cubosomes
- Drug Targets
- Insilico
- Lipids
- Machine-learning approach
- Mitochondria
- Neurodegeneration
- Neuroinflammation
- Oxidative Stress
- Phytocompounds in Alzheimer's Disease
- γ -secretase and γ -Secretase inhibitors

Guest Editor

Dr. Athanasios Alexiou

Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, NSW 2770, Australia and AFNP Med Austria, 1030 Wien, Austria

Deadline for manuscript submissions

closed (30 April 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/121848

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).